AI insight at BIO, Google and Mayo Clinic’s latest effort, & $13 million for health workforce tech

At a BIO panel moderated by STAT’s Torie Bosch yesterday, Amit Etkin, founder of Alto Neuroscience, argued that it’s time for a paradigm shift in how we develop drugs for mental illness. Instead of the current approach — in which people are grouped largely by symptoms — he envisions a future in which diagnoses are broken down by biomarkers. Identifying these biomarkers, and then developing drugs to target them, is increasingly possible with machine learning, he said.